RedHill will receive an initial payment from Hyloris and could potentially earn up to $60 million based on achieving certain goals. Some of the medications involved include Talicia and Aemcolo.
Idorsia, a pharmaceutical company, couldn’t finalize a deal with a potential buyer. To manage its finances, the company modified an existing partnership and reorganized its bonds to raise money. Some of the medications they are known for include Daridorexant, a sleeping aid, and Lucerastat, used for treating certain rare diseases.
The Phase III DIAMOND trial successfully achieved its main goals and additional targets by reducing tics in both children and adult patients. Unfortunately, the text you provided does not mention specific pill names, so I can’t include them.
Eikon’s main drug, EIK1001, is being tested for treating melanoma, a type of skin cancer. It’s being combined with another drug called Keytruda in a Phase III clinical trial.
The company’s decision brings its total investment commitments in the U.S. to over $50 billion since 2020.
The therapy is meant for people whose disease got worse after receiving platinum-based chemotherapy. Some common medications in this category include cisplatin and carboplatin.
The FDA plans to decide by July 30, 2025, whether to grant quick approval for a drug called odronextamab, which treats a type of cancer known as relapsed or refractory follicular lymphoma. This decision could bring a new treatment option to patients who have not responded well to other medicines.
Astellas and Apellis are two companies competing in the U.S. to treat geographic atrophy (GA), a serious eye condition that
Earlier this year, EyePoint Pharmaceuticals faced setbacks when their drug-device combination, Duravyu, did not perform well in a study for
Here’s a simplified version of the text: **Key People at IQVIA** – Nancy McGee: VP of U.S. Patient Support Services